Ascendis Pharma A/S Ordinary Share (ASND)
Nasdaq · Common stock
As of Oct 21, 2:16 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow ASND in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on ASND and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
ASND at a glance
Key statistics
$15.42B
Market capitalization
- Previous close
- $234.33
- Open
- $237.10
- Day range
- $235.56 – $240.47
- Volume
- 299.2K
- Average volume (30 sessions)
- 874.0K
- Shares outstanding
- 65.80M
- Beta (1 year, vs SPY)
- 0.27
Where the price sits in its year
52-week range
55% of the range
- Below the 52-week high
- -15.4%
- Above the 52-week low
- +28.3%
Completed sessions through Oct 20, 2026
Technical snapshot
Below its 50-day and 200-day averages
- 20-day average
- $227.42+3.0%
- 50-day average
- $243.21-3.7%
- 200-day average
- $236.69-1.0%
Between the conventional 30 and 70 bands.
+5.0%
1 week
-1.4%
1 month
-7.0%
3 months
+9.9%
Year to date
+11.3%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with ASND
ASND on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on ASND.
See the plans →
Every planScreen names like ASND
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on ASND
Put ASND on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on ASND
See whether there is an open premium alert on ASND, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
ASND headlines
- Ascendis Announces Planned $400 Million Share Repurchase Program
GlobeNewswire Inc. · Sep 14, 2026
- Why Is Ascendis Pharma Stock Gaining Friday?
Benzinga · Jun 12, 2026
- Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026
GlobeNewswire Inc. · Jun 8, 2026
- Ascendis Pharma to List Ordinary Shares Directly on Nasdaq
GlobeNewswire Inc. · Apr 8, 2026
- Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc. · Jan 9, 2026
- Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia
GlobeNewswire Inc. · Nov 25, 2025
- BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish
Benzinga · Sep 25, 2024
- Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
GlobeNewswire Inc. · Sep 19, 2024
SEC Form 4, most recent first
Insider filings
BIENAIME JEAN JACQUES
−9.2K
Director · Returned to the company
· Apr 14, 2026
BIENAIME JEAN JACQUES
+9.2K
Director · Grant or award
· Apr 14, 2026
Bodenhoff Mads
−3.0K
SVP & PAO · Option exercise
· Sep 8, 2026
Bodenhoff Mads
−3.0K
SVP & PAO · Open-market sale
$810.57K · Sep 8, 2026
Bodenhoff Mads
+3.0K
SVP & PAO · Option exercise
$330.00K · Sep 8, 2026
HOLTUG LARS
−236
Director · Open-market sale
$62.33K · Sep 2, 2026
BIENAIME JEAN JACQUES
+1.1K
Director · Open-market purchase
$270.44K · Aug 14, 2026
BIENAIME JEAN JACQUES
+900
Director · Open-market purchase
$222.22K · Aug 14, 2026
About Ascendis Pharma A/S Ordinary Share
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
- Exchange
- Nasdaq
- Security
- Common stock
- Employees
- 1,189
- Listed since
- Apr 20, 2026
- Website
- ascendispharma.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.